Genetron (GTH) Stock Forecast, Price Target & Predictions
GTH Stock Forecast
Genetron stock forecast is as follows:
Genetron Financial Forecast
Genetron Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $137.75M | $110.32M | $146.86M | $152.54M | $140.49M | $92.06M | $133.94M | $111.96M | $101.73M |
| Avg Forecast | $321.33M | $300.57M | $281.15M | $230.90M | $216.58M | $178.99M | $167.88M | $168.71M | $160.74M | $112.38M | $106.44M | $142.72M | $150.27M | $140.54M | $90.12M | $130.64M | $108.01M | $91.92M |
| High Forecast | $321.33M | $300.57M | $281.15M | $230.90M | $216.58M | $178.99M | $167.88M | $168.71M | $160.74M | $112.38M | $106.44M | $142.72M | $150.27M | $140.54M | $90.12M | $130.64M | $108.01M | $91.92M |
| Low Forecast | $321.33M | $300.57M | $281.15M | $230.90M | $216.58M | $178.99M | $167.88M | $168.71M | $160.74M | $112.38M | $106.44M | $142.72M | $150.27M | $140.54M | $90.12M | $130.64M | $108.01M | $91.92M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.23% | 1.04% | 1.03% | 1.02% | 1.00% | 1.02% | 1.03% | 1.04% | 1.11% |
Genetron's average Quarter revenue forecast for Sep 22 based on 1 analysts is $160.74M, with a low forecast of $160.74M, and a high forecast of $160.74M. GTH's average Quarter revenue forecast represents a 16.69% increase compared to the company's last Quarter revenue of $137.75M (Jun 22).
Genetron EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-160.83M | $-160.89M | $-162.46M | $-123.18M | $-90.41M | $-108.89M | $-71.85M | $-46.44M | $-2.83B |
| Avg Forecast | $-302.36M | $-282.82M | $-264.55M | $-217.27M | $-203.79M | $-168.42M | $-157.96M | $-158.75M | $-151.25M | $-105.74M | $-100.15M | $-134.29M | $-141.40M | $-132.24M | $-105.64M | $-122.92M | $-101.63M | $-2.61B |
| High Forecast | $-302.36M | $-282.82M | $-264.55M | $-217.27M | $-203.79M | $-168.42M | $-157.96M | $-158.75M | $-151.25M | $-105.74M | $-100.15M | $-134.29M | $-141.40M | $-132.24M | $-84.51M | $-122.92M | $-101.63M | $-2.09B |
| Low Forecast | $-302.36M | $-282.82M | $-264.55M | $-217.27M | $-203.79M | $-168.42M | $-157.96M | $-158.75M | $-151.25M | $-105.74M | $-100.15M | $-134.29M | $-141.40M | $-132.24M | $-126.76M | $-122.92M | $-101.63M | $-3.13B |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.52% | 1.61% | 1.21% | 0.87% | 0.68% | 1.03% | 0.58% | 0.46% | 1.08% |
undefined analysts predict GTH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Genetron's previous annual EBITDA (undefined) of $NaN.
Genetron Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-234.67M | $-168.47M | $-143.90M | $-128.97M | $-91.82M | $-115.04M | $-73.22M | $-48.00M | $-2.83B |
| Avg Forecast | $334.22M | $301.34M | $352.01M | $-100.00M | $-104.69M | $-124.12M | $-128.26M | $-127.59M | $-138.96M | $-157.96M | $-168.23M | $-26.50M | $-23.30M | $-17.82M | $-111.60M | $-33.87M | $-45.92M | $-2.61B |
| High Forecast | $334.22M | $301.34M | $352.01M | $-100.00M | $-104.69M | $-124.12M | $-128.26M | $-127.59M | $-138.96M | $-157.96M | $-168.23M | $-26.50M | $-23.30M | $-17.82M | $-89.28M | $-33.87M | $-45.92M | $-2.09B |
| Low Forecast | $334.22M | $301.34M | $352.01M | $-100.00M | $-104.69M | $-124.12M | $-128.26M | $-127.59M | $-138.96M | $-157.96M | $-168.23M | $-26.50M | $-23.30M | $-17.82M | $-133.92M | $-33.87M | $-45.92M | $-3.14B |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.49% | 1.00% | 5.43% | 5.54% | 5.15% | 1.03% | 2.16% | 1.05% | 1.08% |
Genetron's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GTH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Genetron SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $154.83M | $141.09M | $165.19M | $157.61M | $143.09M | $104.27M | $116.31M | $93.00M | $88.52M |
| Avg Forecast | $338.69M | $316.81M | $296.34M | $243.38M | $228.28M | $188.66M | $176.94M | $177.83M | $169.43M | $118.45M | $112.19M | $150.43M | $158.39M | $148.13M | $94.99M | $137.69M | $113.85M | $81.67M |
| High Forecast | $338.69M | $316.81M | $296.34M | $243.38M | $228.28M | $188.66M | $176.94M | $177.83M | $169.43M | $118.45M | $112.19M | $150.43M | $158.39M | $148.13M | $94.99M | $137.69M | $113.85M | $98.00M |
| Low Forecast | $338.69M | $316.81M | $296.34M | $243.38M | $228.28M | $188.66M | $176.94M | $177.83M | $169.43M | $118.45M | $112.19M | $150.43M | $158.39M | $148.13M | $94.99M | $137.69M | $113.85M | $65.33M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.31% | 1.26% | 1.10% | 1.00% | 0.97% | 1.10% | 0.84% | 0.82% | 1.08% |
Genetron's average Quarter SG&A projection for Sep 22 is $169.43M, based on 1 Wall Street analysts, with a range of $169.43M to $169.43M. The forecast indicates a 9.43% rise compared to GTH last annual SG&A of $154.83M (Jun 22).
Genetron EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-2.53 | $-1.82 | $-1.55 | $-1.40 | $-1.00 | $-1.25 | $-0.80 | $-0.55 | $-85.20 |
| Avg Forecast | $10.79 | $9.73 | $11.36 | $-3.23 | $-3.38 | $-4.01 | $-4.14 | $-4.12 | $-4.49 | $-5.10 | $-5.43 | $-0.86 | $-0.75 | $-0.58 | $-0.35 | $-1.09 | $-1.48 | $-1.85 |
| High Forecast | $10.79 | $9.73 | $11.36 | $-3.23 | $-3.38 | $-4.01 | $-4.14 | $-4.12 | $-4.49 | $-5.10 | $-5.43 | $-0.86 | $-0.75 | $-0.58 | $-0.35 | $-1.09 | $-1.48 | $-1.85 |
| Low Forecast | $10.79 | $9.73 | $11.36 | $-3.23 | $-3.38 | $-4.01 | $-4.14 | $-4.12 | $-4.49 | $-5.10 | $-5.43 | $-0.86 | $-0.75 | $-0.58 | $-0.35 | $-1.09 | $-1.48 | $-1.85 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.50% | 0.34% | 1.81% | 1.86% | 1.74% | 3.55% | 0.73% | 0.37% | 45.94% |
According to undefined Wall Street analysts, Genetron's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GTH previous annual EPS of $NaN (undefined).
Genetron Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DRIO | DarioHealth | $0.80 | $10.75 | 1243.75% | Buy |
| MDXH | MDxHealth SA | $1.67 | $15.00 | 798.20% | Buy |
| ACRS | Aclaris Therapeutics | $3.14 | $14.00 | 345.86% | Buy |
| NOTV | Inotiv | $2.72 | $7.33 | 169.49% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| BDSX | Biodesix | $1.26 | $3.00 | 138.10% | Buy |
| XGN | Exagen | $3.00 | $5.00 | 66.67% | Buy |
| CSTL | Castle Biosciences | $27.90 | $40.50 | 45.16% | Buy |
| SHC | Sotera Health Company | $13.88 | $17.43 | 25.58% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |